Drug Trial Radar · NCT07654751
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Aug 7, 2026
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications. This is a fully remote (virtual) study. Participants can complete all study-related activities, including consent, study visits, and breast milk sample collection, from home without attending an in-person study site.
Conditions
- Psoriasis
- Colitis, Ulcerative
- Crohn Disease
- Arthritis, Psoriatic
Interventions
Breast Milk Sample CollectionProcedure
Breast milk samples will be collected as per the schedule specified in protocol.
GuselkumabDrug
Guselkumab as prescribed by the participant's treating physician and obtained by the participant outside of the study per the treating physician's practice will be used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Guselkumab Concentrations at Steady State in Breast Milk (Q4W Maintenance Regimen)Time frame: Up to Day 29
- Guselkumab Concentrations at Steady State in Breast Milk (Q8W Maintenance Regimen)Time frame: Up to Day 57
- Estimated Daily Infant Dosage of Guselkumab Q4W Maintenance RegimenTime frame: Up to Day 29
- Estimated Daily Infant Dosage of Guselkumab Q8W Maintenance RegimenTime frame: Up to Day 57
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.